Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
주식 순위 #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
주가
$50.93
시가총액
$226.32B
변동 (1일)
2.54%
변동 (1년)
-26.19%
국가
DK
거래 Novo Nordisk A/S (NVO)

카테고리

Novo Nordisk A/S (NVO)의 수익
Mar 2026 기준 수익 TTM: $24.72B
Novo Nordisk A/S의 최신 재무 보고서에 따르면 회사의 현재 수익은 $24.72B입니다. 2024년에 회사는 $17.75B의 수익을 올렸으며 이는 2023년의 수익 $15.50B과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Novo Nordisk A/S의 수익 기록 (2000 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $24.72B 25.36%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.17B -79.10%
US
$5.16B -79.14%
US
$2.14B -91.35%
BE
$1.48B -94.01%
NL
$586.40M -97.63%
US